Development of Tools Sample Clauses

Development of Tools. From time to time during the Term, Novation may request Neoforma to design Tools for Members or Suppliers in addition to the Tools, functions and APIs, which will be mutually agreed upon and contained in the Functionality Roadmap. Within a reasonable time after such request, appropriate personnel from Novation and Neoforma will meet to discuss and draft technical specifications for the desired customized Tools, functions and APIs.
Sample 1
AutoNDA by SimpleDocs
Development of Tools. In Q3, the project sent 1 M&E staff to attend a National MVC M&E Plan refresher training in Zanzibar which was organized and coordinated by MEASURE Evaluation. This training was also attended by Kizazi Kipya CSOs staff from ZAMWASO, WAMATA Pemba and other partners like JSI and Zanzibar department of Social Welfare. The key outputs in this meeting included pilot testing MVC national tools and revising the tools based on pilot findings. The next step is to train MVC partner’s CSO staff and national volunteers on the National MVC tools. Meanwhile, while awaiting the official tools printing by CHSSP, CSOs continued to photocopy tools for recording service delivery data by volunteers. However, photocopying has not been working well for the referral tool which requires printing on a slightly larger paper size, triplicate copies and a referral slip for tracking referral success. CCWs have been relying on previous Pamoja Tuwalee referral books which are at present out of stock in most areas which has hugely affected documentation of referrals and underreporting. The project is working closely with CHSSP to print need tools for Q4 to improve reporting of referrals. Data Management Systems Set-Up Kizazi Kipya deployed an interim mobile data collection system in Q1 to capture household-level service delivery data, VSLGs, referral and Family and Child Asset Assessment data. The system is based on CommCare platform and enables data entry through tablets and smartphones. The project procured about 450 tablets used for data entry at XXXx using temporary data clerks. By Q2, the total number of temporary data clerks has increased 498 across all CSOs due large amounts of data that need to be entered on quarterly basis with some Wards having over 5,000 beneficiaries, for instance Wazo xxxx in Kinondoni, Dar es Salaam where 6,379 were served in Q1. The project also spent a significant amount of time in Q2 to create and verify profiles of beneficiaries that were enrolled in Kizazi Kipya in Q1. The project also implemented additional logic checks in the mobile app to improve data validation and overall quality. Pact worked with EGPAF to develop the e-referral system. In this quarter the team integration the USSD short code with the top three mobile network operators in the country and is finalizing the technical testing of the USSD data collection for bi-directional referral tracking system. Pact finalized the technical set-up of the DHIS2 software for data entry and data manag...
Sample 1
Development of Tools and guidance that support the use of AMR surveillance data (including AMU/AMC, and SF data) in national policy, practice and investment decisions Further work to establish the importance of collecting data on sub-standard and Falsified Veterinary Products to tackle AMR, and to directly support countries to collect and report such data WOAH Quality of Veterinary Products Programme [Strategic Shift – Substandard and Falsified (veterinary) Medicines] Xxxxxxx Fund has supported the accelerated delivery of this ambitious programme that aims to reduce the circulation of substandard and falsified (SF) veterinary products globally and their contribution to AMR. The programme is based on the creation of an information and alert system for the WOAH Member Focal Points for Veterinary Products, using a similar structure as that successfully used by the World Health Organization (WHO) for surveillance of SF medical products. WOAH’s proposed global information and alert system aims to receive notifications of SF veterinary products from our network of National Focal Points from Members for Veterinary Products, and to subsequently inform all Members through alerts of incidents of SF veterinary products to facilitate their removal from circulation. This system will support a better understanding of SF veterinary products and their contribution to AMR using a coordinated, global approach. Work has begun under Phase 1 to pilot the global information and alert system for SF veterinary products. Continued Xxxxxxx Fund support for the period 2022/25 would enable the continued delivery of this programme shared previously with the Xxxxxxx Fund.. In summary:
Sample 1

Related to Development of Tools

  • Development of Products (a) During the term of this Agreement, ViewRay may from time to time seek services from PEKO with respect to the development of certain Products that can be incorporated into the ViewRay Renaissance™ MRI-guided radiation therapy system. For each Program to be undertaken by PEKO pursuant to this Agreement, the parties will prepare a “Work Statement” and agree to said “Work Statement” in substantially the form attached as Attachment 1. Each Work Statement will describe: (i) the (i) services that PEKO will be responsible for providing to ViewRay and the deliverables that PEKO will be responsible for delivering to ViewRay (“Deliverable(s)”), (ii) delivery schedule for the Deliverables, (iii) pricing terms, (iv) work plan for the Program, and (v) ViewRay’s responsibilities in connection with the Program. Each Work Statement will be prepared based upon the requirements and information provided to PEKO by ViewRay. A separate Work Statement will be required for each Program; and each Work Statement will become subject to this Agreement only when mutually agreed and signed by ViewRay and PEKO.

  • Development Services During the term of this Agreement, the Provider agrees to provide to or on behalf of the Port the professional services and related items described in Exhibit A (collectively, the “Development Services”) in accordance with the terms and conditions of this Agreement. The Provider specifically agrees to include at least one Port representative in any economic development negotiations or discussions in which the Provider is involved concerning (i) a port-related business prospect or (ii) a business transaction which will ultimately require Port involvement, financial or otherwise.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development of the Project 4.1 TSP's obligations in development of the Project: Subject to the terms and conditions of this Agreement, the TSP at its own cost and expense shall observe, comply with, perform, undertake and be responsible:

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.

  • Development Diligence Novartis shall dedicate commercially reasonable efforts, during each [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards the next clinical Development milestone or approval milestone, as described in Sections 7.4.2 or 7.4.3, respectively. If Novartis (itself or through its Affiliates or sublicensees) fails to dedicate commercially reasonable efforts, during any [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards such next milestone, then any dispute regarding Novartis’ failure of development diligence with respect to such Profile shall be resolved in accordance with Article 13.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

Time is Money Join Law Insider Premium to draft better contracts faster.